» Articles » PMID: 38509890

The Importance of Protein Domain Mutations in Cancer Therapy

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Mar 21
PMID 38509890
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is a complex disease that is caused by multiple genetic factors. Researchers have been studying protein domain mutations to understand how they affect the progression and treatment of cancer. These mutations can significantly impact the development and spread of cancer by changing the protein structure, function, and signalling pathways. As a result, there is a growing interest in how these mutations can be used as prognostic indicators for cancer prognosis. Recent studies have shown that protein domain mutations can provide valuable information about the severity of the disease and the patient's response to treatment. They may also be used to predict the response and resistance to targeted therapy in cancer treatment. The clinical implications of protein domain mutations in cancer are significant, and they are regarded as essential biomarkers in oncology. However, additional techniques and approaches are required to characterize changes in protein domains and predict their functional effects. Machine learning and other computational tools offer promising solutions to this challenge, enabling the prediction of the impact of mutations on protein structure and function. Such predictions can aid in the clinical interpretation of genetic information. Furthermore, the development of genome editing tools like CRISPR/Cas9 has made it possible to validate the functional significance of mutants more efficiently and accurately. In conclusion, protein domain mutations hold great promise as prognostic and predictive biomarkers in cancer. Overall, considerable research is still needed to better define genetic and molecular heterogeneity and to resolve the challenges that remain, so that their full potential can be realized.

Citing Articles

Targeting senescence and GATA4 in age-related cardiovascular disease: a comprehensive approach.

Imran M, Altamimi A, Afzal M, Babu M, Goyal K, Ballal S Biogerontology. 2025; 26(1):45.

PMID: 39831933 DOI: 10.1007/s10522-025-10189-z.


Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review.

Saxena R, Welsh C, He Y Front Cell Dev Biol. 2024; 12:1462339.

PMID: 39620145 PMC: 11604647. DOI: 10.3389/fcell.2024.1462339.


Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?.

Giuliani P, De Simone C, Febo G, Bellasame A, Tupone N, Di Virglio V Int J Mol Sci. 2024; 25(18).

PMID: 39337267 PMC: 11431518. DOI: 10.3390/ijms25189778.

References
1.
Scheffold A, Jebaraj B, Stilgenbauer S . Venetoclax: Targeting BCL2 in Hematological Cancers. Recent Results Cancer Res. 2018; 212:215-242. DOI: 10.1007/978-3-319-91439-8_11. View

2.
Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View

3.
Gromiha M, Selvaraj S . Inter-residue interactions in protein folding and stability. Prog Biophys Mol Biol. 2004; 86(2):235-77. DOI: 10.1016/j.pbiomolbio.2003.09.003. View

4.
Murdande S . Role of rat sarcoma virus mutations in cancer and potential target for cancer therapy. Future Sci OA. 2020; 6(4):FSO455. PMC: 7117548. DOI: 10.2144/fsoa-2019-0045. View

5.
Drilon A, Subbiah V, Gautschi O, Tomasini P, De Braud F, Solomon B . Selpercatinib in Patients With Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol. 2022; 41(2):385-394. PMC: 9839260. DOI: 10.1200/JCO.22.00393. View